Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2010, Article ID 856542, 4 pages
http://dx.doi.org/10.1155/2010/856542
Research Article

Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients

1Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2College of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, USA
3Pharmacy Department, Durham Veterans Affairs Medical Center, Durham, NC 27705, USA
4Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA

Received 30 January 2010; Revised 8 June 2010; Accepted 6 September 2010

Academic Editor: Peter P. Koopmans

Copyright © 2010 Emily L. Heil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results. Fifty-six of the 544 patients identified met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients). Severe hepatotoxicity occurred with efavirenz ( 𝑁 = 2 ), nevirapine ( 𝑁 = 1 ), indinavir ( 𝑁 = 1 ), nelfinavir ( 𝑁 = 1 ), and saquinavir/ritonavir ( 𝑁 = 1 ). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen.